San Francisco, CA (PRWEB) November 09, 2011

Bristol-Myers Squibb Organization (NYSE: BMY) today declared 96-week results from the Beneath examine, a Phase IIIb clinical trial comparing BARACLUDE monotherapy (.5mg once every day) with BARACLUDE (.5mg when day-to-day) plus tenofovir (300mg as soon as everyday) in treatment-na